Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Transcranial Direct Current Stimulation on Fatigability and Fatigue Induced by a Selective Attention Task

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02840214
Recruitment Status : Withdrawn (Study was never initiated.)
First Posted : July 21, 2016
Last Update Posted : July 2, 2017
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This research project is focusing on changes in mental fatigue due to transcranial direct current stimulation (tDCS) in healthy individuals. The study aim is to see if mental fatigue can be rescued by administering a safe dose of tDCS. tDCS has been shown to decrease fatigue in healthy individuals experiencing extended wakefulness, and the investigators aim to investigate if similar results can be found in a fatigue inducing task. This is a single-blind randomized control trial that will compare mental fatigue between tDCS treatment and sham treatment groups through both subjective and objective measures. Objective fatigue will be measured by reaction time with the Stroop test and subjective fatigue will be measured by the multidimensional fatigue inventory questionnaire.

Condition or disease Intervention/treatment Phase
Fatigue Device: transcranial direct current stimulation Device: sham tDCS Phase 1

Detailed Description:
Right handed healthy individuals aged 18-40 will be eligible to participate. Participants will be randomized in a 1:1:1 ratio to receive real or placebo 2mA tDCS delivered for 20 minutes while performing a 3 hour computerized cued Stroop task. Groups will receive real or sham stimulation during the first 20 minutes or 90-110 minutes into the task. Groups will be: 1) Sham (sham given at both time points); 2) Prevent (real will be given during first 20 minutes to try to prevent or delay fatigue and sham given at second time point); or 3) Rescue (sham will be given initially and real given at 90-110 minutes to see if performance can be rescued after fatigue has set in). The primary outcome measure will be the slope of change for intra-individual variability of response time for correct items and regression models will be used to determine whether real preventative or rescue tDCS alters the rate of performance change relative to sham stimulation. Accuracy and mean response time will also be examined as secondary outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Estimated Primary Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue

Arm Intervention/treatment
Active Comparator: tDCS rescue group
Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
Device: transcranial direct current stimulation
Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
Other Name: tDCS

Placebo Comparator: Sham Treatment Group
Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
Device: sham tDCS
Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
Other Name: Placebo

Active Comparator: tDCS prevent group
Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
Device: transcranial direct current stimulation
Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
Other Name: tDCS




Primary Outcome Measures :
  1. Change in cognitive performance fatigability [ Time Frame: over 3 hours of a single fatigability task (one time visit study) ]
    This will be measured by change in intraindividual variability of reaction time from the Stroop Fatigue Paradigm which will be quantified as the rate of change in mean reaction time over 3 hours modeled using linear regression.


Secondary Outcome Measures :
  1. Change in perceived fatigue [ Time Frame: Baseline then every 30 minutes for 3 hours ]
    This will be assessed by visual analogue scale of fatigue performed at baseline and every 30 minutes of the task and the slope of change in perceived fatigue modeled using linear regression.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • right-handed
  • normal or corrected-normal vision,

Exclusion Criteria:

  • pregnant women,
  • history of medical conditions associated with fatigue, including, but not limited to:

    • Parkinson's disease,
    • Alzheimer's disease,
    • diabetes mellitus,
    • hypothyroidism,
    • chronic fatigue syndrome,
    • anemia,
    • infectious mononucleosis,
    • irritable bowel syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02840214


Locations
Layout table for location information
United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Benzi Kluger, MD University of Colorado, Denver

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02840214     History of Changes
Other Study ID Numbers: 15-1035
First Posted: July 21, 2016    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Deidentified data may be released to other researchers upon request.

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatigue
Signs and Symptoms